Radiotherapy for undifferentiated spindle cell sarcoma of the prostate: a case report
10.3760/cma.j.cn112330-20250806-00327
- VernacularTitle:放疗治疗前列腺未分化梭形细胞肉瘤1例报告
- Author:
Yuyang ZHAO
1
;
Hongzhen LI
;
Wei YU
;
Huan ZHANG
;
Shuai HU
;
Xuhe LIAO
;
Xin QI
Author Information
1. 北京大学第一医院放射治疗科，北京 100034
- Publication Type:Journal Article
- Keywords:
Prostate sarcoma;
Radiotherapy;
Stereotactic body radiation therapy;
Quality of life
- From:
Chinese Journal of Urology
2025;46(10):788-790
- CountryChina
- Language:Chinese
-
Abstract:
Undifferentiated spindle cell sarcoma of the prostate is clinically rare. This article reports a case of a 29-year-old male who presented on February 7，2022，with a two-week history of localized pain in the perineal area and spermatic cord. The diagnosis of prostatic undifferentiated spindle cell sarcoma was confirmed by imaging studies and prostate needle biopsy pathology. After consultation by the urologic oncology multidisciplinary team and considering the patient's preference，a treatment plan of radical radiotherapy combined with chemotherapy，immunotherapy，and targeted therapy was adopted，Partial stereotactic body radiotherapy（P-SBRT）was delivered to the tumor center with a total dose of 74.4 Gy，combined with cisplatin and pembrolizumab. Lung metastasis progression occurred 1.5 months after radiotherapy，and treatment was switched to a combination of pirarubicin，ifosfamide，pembrolizumab，and bevacizumab. After 39 months of follow-up，the disease remained well-controlled with preserved organ function and long-term survival. This case，utilizing a multidisciplinary comprehensive diagnosis and treatment model，provides a reference for organ-preserving non-surgical management in patients with prostate soft tissue sarcoma.
